Concord Wealth Partners Mirum Pharmaceuticals, Inc. Transaction History
Concord Wealth Partners
- $673 Million
- Q2 2025
A detailed history of Concord Wealth Partners transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 5 shares of MIRM stock, worth $259. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5Holding current value
$259% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MIRM
# of Institutions
228Shares Held
55.4MCall Options Held
27.4KPut Options Held
105K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.8MShares$352 Million19.27% of portfolio
-
Janus Henderson Group PLC London, X04.77MShares$247 Million0.12% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$168 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.8MShares$145 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$132 Million0.0% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.9B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...